Sustainable Transformation Enabling the Future of Paris as a Smart City zazoom.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zazoom.it Daily Mail and Mail on Sunday newspapers.
Share:
ResearchAndMarkets.com s offering.
Major players in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) market are Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh and AstraZeneca.
The global anti-asthmatics and copd drugs market is expected to decline from $75.38 billion in 2020 to $66.81 billion in 2021 at a compound annual growth rate (CAGR) of -11.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $86.44 billion in 2025 at a CAGR of 6.7%.
The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-
Share:
ResearchAndMarkets.com s offering.
This report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology as well as the CVU market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The CVU market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CVU market size from 2017 to 2030. The report also covers current CVU treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Scope of the Report
Share:
ResearchAndMarkets.com s offering.
The value of the pneumococcal vaccines market will steadily grow over the forecast period due to increasing elderly populations across France, Spain, and the US, alongside continued short-term price increases in the lucrative US market.
A brief period of increased growth is expected with the anticipated launch of the 20-valent vaccine, PF-06482077, which may replace Prevnar 13 and Pneumovax 23 in adults (from June 2021) and Prevnar 13/V114 in infants (from mid-2023). Overall, the biggest opportunity for short-term growth within the pneumococcal vaccines market is associated with increasing vaccination rates within the elderly in the US and Italian markets; however, the 2019 reversal of the original 2014 ACIP recommendation for Prevnar 13 s use in the elderly population will hamper its growth in the US.
Global Leak Detection and Repair Market Size, Share & Trends Analysis Report 2021-2028 padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.